2 results
Approved WMOCompleted
To evaluate the tolerability (adverse effects) of 99mTc-Fucoidan in 10 healthy volunteers (phase I).
Approved WMORecruiting
Study AMAP is a single-arm, outpatient, open-label, Phase 3, multicenter, long-term extension study evaluating the efficacy and safety of mirikizumab in patients with moderately to severely active UC who have participated in an originator…